ArchPoint Investors’s Rocket Pharmaceuticals RCKT Stock Holding History

ArchPoint Investors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,000	Closed	-$32.6K	–	82
2025 Q3	$32.6K	Buy	+10,000	New	+$31.5K	0.01%	72
2020 Q3	–	Sell	-1,500	Closed	-$31K	–	119
2020 Q2	$31K	Hold	1,500	–	–	0.01%	107
2020 Q1	$21K	Hold	1,500	–	–	0.01%	127
2019 Q4	$34K	Hold	1,500	–	–	0.01%	124
2019 Q3	$17K	Buy	+1,500	New	+$18.6K	0.01%	129

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

ArchPoint Investors's RCKT Position: Q4 2025 in Review

ArchPoint Investors sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 10,000 shares — an estimated $32.6K sold.

ArchPoint Investors first reported a position in RCKT in Q3 2019 and held it in 5 quarters. The position peaked at $34K in Q4 2019. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

ArchPoint Investors reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
ArchPoint Investors sold 10,000 Rocket Pharmaceuticals shares in Q4 2025, an estimated $32.6K.
ArchPoint Investors first reported a position in Rocket Pharmaceuticals in Q3 2019 and held it in 5 quarters.
ArchPoint Investors's Rocket Pharmaceuticals position peaked at $34K in Q4 2019.
186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on ArchPoint Investors's 13F filing for Q4 2025, filed 13 Feb 2026.